Peptide questions · Survodutide
Survodutide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for survodutide are nausea, vomiting and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: survodutide has no label.
What is commonly reported with survodutide
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Fatigue
- Higher resting heart rate
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 5 more |
| Fatigue | 7: Semaglutide, Tirzepatide, Retatrutide, Dulaglutide and 3 more |
| Higher resting heart rate | None: listed for Survodutide alone |

Model. Individual results vary.
Which survodutide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Survodutide shares 6 of its 7 listed effects with at least one other metabolic & GLP-1 compound; higher resting heart rate is listed for survodutide alone.
What the survodutide safety notes say
The library’s safety note
Survodutide has no label. In phase 3, GI side effects were the most common, mostly mild to moderate and clustered in the dose climb: in SYNCHRONIZE-1 they affected 80.9% (3.6 mg) and 89.7% (6.0 mg) vs 47.9% on placebo; at 6.0 mg in SYNCHRONIZE-MASLD, nausea affected 56% and vomiting 43%, and 20% stopped for GI reasons (4% on placebo). Resting heart rate rose about 3.6 beats per minute (0.8 on placebo). Its phase 3 trials leave out people with a personal or family history of medullary thyroid carcinoma or MEN 2, or a history of pancreatitis, as GLP-1 trials do; SYNCHRONIZE-MASLD saw no confirmed pancreatitis or drug-induced liver injury on survodutide. These are trial findings; review them with your clinician.
The library’s interaction note
No dedicated interaction studies are published beyond the GLP-1 class effect on stomach emptying: in phase I, a single 1.2 mg dose strongly reduced paracetamol absorption (Boehringer Ingelheim protocol). It is a GLP-1 receptor agonist itself, so it is not combined with another GLP-1 drug. Its glucagon arm raises resting heart rate a little, worth raising with your clinician alongside stimulants or a fast heart rhythm. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the survodutide reports come from
The library rates the evidence on survodutide as established: clinical trials or FDA-approved use exist.
Of the library’s 7 research notes on survodutide, 6 rest on randomized trials and 1 on community reports.
Our 4 study pages on survodutide: 3 randomized trials and 1 animal study (mice).
So survodutide has controlled trials in people to set its listed effects against.
What our survodutide study pages report on safety
Survodutide: up to 13.0% weight loss at 76 weeks in SYNCHRONIZE-1
Randomized trial, human, 2026: Digestive complaints led the list of side effects, and most cases were mild or moderate: 80.9% of the 3.6 mg arm, 89.7% of the 6.0 mg arm and 47.9% of the placebo arm had them. In a large 76-week phase 3 trial, weekly survodutide led to more weight loss than placebo in people with obesity but no diabetes, and digestive side effects were common.
Survodutide: 12.2% weight loss and less liver fat at 48 weeks
Randomized trial, human, 2026: The most common side effects were gastrointestinal, often during dose increases, and mostly mild to moderate. This phase 3 trial adds evidence that survodutide lowered liver fat and body weight more than placebo over 48 weeks in adults with obesity and at-risk fatty liver disease, with mostly gastrointestinal side effects.
Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trial
Randomized trial, human, 2024: Side effects showed up in 281 of 309 (91%) people on survodutide and 58 of 77 (75%) on placebo. In this phase 2 trial, survodutide lowered bodyweight more than placebo at every dose tested, with larger losses at higher doses and gut side effects in most people taking it.
Questions people ask
What are the side effects of survodutide?
The side effects most commonly reported for survodutide are nausea, vomiting and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Do survodutide’s side effects come from human studies?
The library rates the evidence on survodutide as established, and the library’s evidence on it includes controlled trials in people.
Which survodutide side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists higher resting heart rate for survodutide alone.
Does survodutide interact with other medicines?
The library’s interaction note on survodutide begins: No dedicated interaction studies are published beyond the GLP-1 class effect on stomach emptying: in phase I, a single 1.2 mg dose strongly reduced paracetamol absorption (Boehringer Ingelheim protocol).